PGS Publication: PGP000123

Publication Information (EuropePMC)
Title Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.
PubMed ID 32321713(Europe PMC)
doi 10.1158/1055-9965.epi-19-1389
Publication Date April 22, 2020
Journal Cancer Epidemiol Biomarkers Prev
Author(s) Kim J, Yuan C, Babic A, Bao Y, Clish CB, Pollak MN, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Pandharipande PV, Brais LK, Welch MW, Ng K, Giovannucci EL, Sesso HD, Manson JE, Stampfer MJ, Fuchs CS, Wolpin BM, Kraft P.
Released in PGS Catalog: Jan. 7, 2021

Associated Polygenic Score(s)

PGS Developed By This Publication

Polygenic Score (PGS) ID PGS Name PGS Publication (PGP) ID Reported Trait Mapped Trait(s) (Ontology) Number of Variants PGS Scoring File (FTP Link)
PGS000663 wGRS22 PGP000123 Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) Pancreatic cancer pancreatic carcinoma 22 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000663/ScoringFiles/PGS000663.txt.gz

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID)
Evaluated Score PGS Sample Set ID
(PSS ID)
Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM001367 PGS000663 (wGRS22) PSS000598 PGP000123
Kim J et al. (2020)
Reported Trait: Pancreatic cancer OR: 1.37 [1.23, 1.53] Cross validation approach-testing sample = 20%
PPM001368 PGS000663 (wGRS22) PSS000597 PGP000123
Kim J et al. (2020)
Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.46 [1.27, 1.68] Cross validation approach-testing sample = 20%
PPM001369 PGS000663 (wGRS22) PSS000598 PGP000123
Kim J et al. (2020)
Reported Trait: Pancreatic cancer OR: 1.37 [1.22, 1.53] AUROC: 0.65 matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%
PPM001370 PGS000663 (wGRS22) PSS000597 PGP000123
Kim J et al. (2020)
Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.44 [1.25, 1.67] AUROC: 0.67 matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%

Evaluated Samples

PGS Sample Set ID
(PSS ID)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000597 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. Cases Diagnosed within 10 years of blood collection. Mean = 10.0 years
[
  • 304 cases
  • , 652 controls
]
,
28.1 % Male samples
European HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)
PSS000598 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data.
[
  • 500 cases
  • , 1,091 controls
]
,
33.4 % Male samples
European HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)